Xin Lang Cai Jing·2025-10-31 06:27Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s (INBX.US) DR5-targeting antibody, ozekibart, in treating advanced or metastatic, unresectable sarcoma patients [1] Company Summary - Chuangsheng Group's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] - The company holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1] Industry Summary - Inhibrx Biosciences announced positive primary results from a registrational clinical study evaluating the efficacy of ozekibart compared to placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Inhibrx plans to submit a marketing application for ozekibart for soft tissue sarcoma indications to U.S. regulatory authorities by the end of June 2026 [1]